¹B°Ê¥Í²z¶g°T(²Ä132´Á)
¦Ù»Ä»P¹B°Êªí²{(Octocber.05, 2002)
¾G´º®p
³ü¡B«e¨¥
¡@¡@¦Û±q1992¦~¤Ú¶ë¶©¯Ç¶ø¹B·|¤W¡A¹Ü±o100¤½¤Øµu¶]ª÷µPªº^°ê¦W±NLinford Christie¡A¥H¤Î110°ªÄ檺Colin Jackson´£¥X¦Ù»Ä¼W¸É¹ï¥L̪º¹B°Ê¦¨ÁZ½T¹ê¦³À°§U¤§«á¡A±Û§Y³y¦¨¦Ù»Ä¼W¸Éªº¥@¬É·¼é¡C¦Ó¥Ø«e¦Ù»Äªº¨Ï¥Î¡A¨Ã¥¼³Q°ê»Ú¶øªL¤Ç§J©eû·|(IOC, International Olympic Committee)¦C¬°¸TÃĤ§¦C¡A¤]¦]¦¹¿E°_¤F±Ð½m»P¹B¬ì¤Hû¹ï©ó¦Ù»Ä¼W¸Éªºª`·N¤O¡C
¡@¡@¬°¤FÁA¸Ñ¦Ù»Ä¼W¸Éªº½T¹ê®ÄªG¡A¥»¤å§Y°w¹ï¦Ù»Ä¦bÅ餺¥NÁ¨t²Î¤¤©Ò§êºtªº¨¤¦â¡B¦Ù»Ä¼W¸É¹ï¹B°Êªí²{ªº¼vÅT¡B¦Ù»Ä¼W¸Éªk¤Î¨ä¼vÅT¦]¯Àµ¥¼h±¥[¥HÄÄz¡A¥H´Á¹ï¦Ù»Ä¼W¸Éªº§Q¹ú°µ¤@¥þ½L©Êªº»{ÃÑ¡A¨Ã´£¨Ñ¥¼¨Ó¬ã¨sªÌ»P±Ð½m¦b¹ê¬I¦Ù»Ä¼W¸Éªk®É¡A¯à¦³¾A·íªº¥Í²z¾Ç¤W»PÀç¾i¾Ç¤WªºI´ºª¾ÃÑ¡C
¶L¡B¦Ù»Ä»P¯à¶q¨t²Î
¡@¡@¦Ù»Ä¬O¤@ºØ¤ÑµMªº¤Æ¦Xª«¡A¥ÑºëÓi»Ä(arginine)¡B苷Ói»Ä(glycine)»P¥Ò²¸Ói»Ä(methionine)¦b¨xŦ¡BµÇŦ»P¯ØÅ¦¤º©Ò¦X¦¨¡A¦AÂǥѦå²Gªº´`Àô¹B°e¦Ü°©Àf¦Ù¡A¥H¦Ù»Ä©ÎªÌÁC»Ä¦Ù»Ä(PCr, phosphocreatine)ªº«¬¦¡Àx¦s¡A´£¨Ñ¨Åé©Ò»Ý¡C³½¡B¦×¡B³J¤Î¨ä¥L°Êª«©Ê»s«~¤¤¬Ò§t¦³¦Ù»Ä¡A¦Ó½µæ¤¤¥ç¦³·¥¤Öªº§t¶q¡C¨C¤H¨C¤é©Ò®ø¯Óªº¦Ù»Ä¶q¡A¬ù¬°Å餺Á`¦Ù»Ä¶qªº1.6%¡A¦]¦¹¡A¤@Ó70¤½¤çªº¥¿±`¤H¨C¤é»Ý®ø¯Ó2§Jªº¦Ù»Ä¡AÂǥѧ¡¿Åªº¶¼¹§Y¥iÀò±o¨¬°÷ªº¸É¥R(±iīī¡A¥Á88)¡C¹B°Êû¦b°ª±j«×ªº¿E¯P¹B°Ê¤U¡A«h»ÝnÂÇ¥ÑÅ餺¦Ù»Äªº¤£Â_¦X¦¨²£¥Í¯à¶q¥Hºû«ù©Ò»Ý¡A¦ÓÅ餺¦Ù»Ä¦X¦¨¶q¦³¡A¤@¯ëªº¶¼¹¥i¯à¤´µLªkº¡¨¬©Ò»Ý¡A¦]¦¹¡A¥i³z¹L¦Ù»Äªº¼W¸É´£¨Ñ¨Åé©Ò»Ý¡Aºû«ù¹B°Êªí²{¡C
¡@¡@Å餺¦Ù»Ä¿@«×³Ì°ªªº³¡¦ì¦b°©Àf¦Ù¡A¬ù¦ûÅ餺Á`¦Ù»Äªº95%¡A¨ä¤¤¥]§t¤F40%ªº´åÂ÷¦Ù»Ä(free creatine)»P60%ªºÁC»Ä¦Ù»Ä¡C¥t¥~¡A¦b¤ßŦ¡Bºë¤l¡Bµøºô½¤»P¸£¤¤¤]§t¦³¤Ö³¡¤À(5%)¡CÅ餺°©Àf¦Ùªº¦Ù»Ä§t¶q¬ù¬°90~160 mM/kg d.m.¡A¥§¡È¬°125 mM/kg d.m.(McArdleµ¥¤H¡A2001)¡C¦Ù»Ä»PPCrªº¿@«×¤]©M°©Àf¦ÙªºÁ޸ѯà¤O¦³Ãö¡A§ÖÁY¦ÙÅÖºû(Type Iia»PType Iib)¤ºªºPCr¿@«×¸ûºCÁY¦ÙÅÖºû(Type I)°ª(±iīī)¡C§ÖÁY¦ÙÅÖºû¤ºªºPCrÀx¦s¶q¬OATPªº4~6¿(McArdleµ¥¤H)¡C
¡@¡@¦b¹B°Ê¹Lµ{¤¤¡AATP¬O¯à¶qªº°ò¥»¨Ó·½¡A¹B°Ê±j«×¶V±j¡A®ø¯Ó¶V¤j¡C¦b³Ì¤j¹B°Ê®É¡A¦Ù¦×¤¤ATPªºÁ`¶q¥u¨¬°÷À³¥I¦Ù¦×«ùÄò2~3¬íªº¹B°Ê¡A¦]¦¹¡A»ÝÂÇ¥ÑATP¤£Â_ªº¦A¦X¦¨¥Hºû«ù©Ò»Ý¯à¶q¡CÁöµMATP¦A¦X¦¨ªº¥Dn¨Ó·½¡A·½¦Û©ó¯×ªÕ»P¨xÁÞªº¤À¸Ñ¡AµM¦Ó¡A¦¹®ÉªºATP¦A¦X¦¨§@¥Î»Ýn¸ûªøªº®É¶¡¡A¦]¦¹¡A¦b°ª±j«×µu®É¶¡ªº¹B°Ê®É¡A¤ñ¦p5~8¬íªº½Ä¨ë¶]¡A¥Ñ¯×ªÕ»P¨xÁÞÂà´«¦¨ATPªº³t«×¡A±N¤£¨¬¥HÀ³¥I¦¹®Éªº¯à¶q»Ý¨D¡C¦b°ª±j«×µu®É¶¡ªº¹B°Ê¤¤¡A¨Ò¦p100¤½¤Ø½Ä¨ë¶]¡B25¤½¤Ø´åªa©ÎÁ|«¡A¨ä¯à¶qªº¸É¥R¨Ó¦Û©ó¦Ù¦×¤ºªº°ª¯àÁC»ÄÁä(high-energy phosphates)©ÎÁC»Ä®Ú(phosphagens)¡BATP¥H¤ÎÁC»Ä¦Ù»Ä¡C
¡@¡@¹Ï¤@¤¤Åã¥Ü¤FATP»PPCr¨Ï¥ÎÁC»ÄÁä¯à¶qªº±¡§Î¡CATP»PPCr¨ã¦³¬Û¦Pªº¯S½è¡F(1)¥¦Ì§¡³z¹LÁC»ÄÁ䪺Â_µõ¦ÓÄÀ©ñ¥X¯à¶q¡APCr¬O³z¹L¦Ù»Ä(creatine)»PÁC»Ä(phosphate)¤À¤l¤§¶¡Áäµ²ªºÂ_µõ¡F(2)ATP»PPCrÄÀ©ñ¯à¶qªº¤ÏÀ³¡A§¡¨ã¦³¥i°f©Ê¡A¥ç§YÁC»Ä»P¦Ù»Ä¤]¥i¥H¦AÁäµ²¦Ó§Î¦¨PCr¡F¦ÓADP»PPiªºÁäµ²¡A¥i¦A¦X¦¨ATP¡C¦]¬°PCr¦b¤ô¸Ñ®É²£¥Íªº¯à¶q¸û°ª©óATPªº¤ô¸Ñ¯à¶q(McArdleµ¥¤H)¡A¦Ó³o¨Ç¯à¶q±N¥i´£¨Ñ§@ADPÂà´«¦¨ATPªºÁC»Ä¤Æ¤ÏÀ³(phosphorylation)¡CPCrªº¤ô¸Ñ¤ÏÀ³¡A¥²¶·ÂǥѦٻĿE酶(CK, creatine kinase)ªº¶Ê¤Æ¡A¦Ù»Ä¿E酶¦³4~6%¦ì¦b²É½uÅé¥~½¤(outer mitochondrial membrane)¤º¡A3~5%¦ì©ó¦Ù¸`(sarcomere)¤¤¡A¦Ó¦³90%¦ì©ó²ÓM²G(cytosol)¤º(McArdleµ¥¤H)¡C
¡@¡@·í¦Ù¦×¬¡°Ê®É¡A·|³y¦¨¦Ù¦×¤ºADPªºÀþ¶¡¼W¥[¡A³o·|¨Ï±o¦Ù»Ä¿E酶¶}©lÅX°ÊPCrªº¤ô¸Ñ§@¥Î¡A¶i¦Ó²£¥ÍATP¡F¦¹®Éªº¤ÏÀ³¡A¨Ã¤£»Ýn®ñ®ðªº¤¶¤J¡A¦Ó¥¦¥i´£¨Ñªº³Ì¤j¯à¶q½d³ò¡A¤j¬ù¬O¦b10¬í¤ºªº¿E¯P¨Å鬡°Ê¡C¦]¦¹¡APCr´£¨Ñ¤F¤@Ó°ª¯àÁC»ÄÁ䪺ÀxÂëǡC¥Ñ©ó¦Ù»Ä¿E酶¨ã¦³¸û°ªªº¬¡©Ê¡A¦]¦¹¡AADPÁC»Ä¤Æ¤ÏÀ³ªº³t«×·|°ª©ó¦Ù¦×¨xÁÞ©Ò¶i¦æªºµL®ñ¯à¶qÂà´«(¿}¸Ñ§@¥Î¡Aglycolysis)¡C¦pªG³Ì¤j§V¤O¹B°Ê©Ò«ùÄòªº®É¶¡¶W¹L10¬í®É¡AATPÄ~Äò¦A¦X¦¨ªº¤ÏÀ³¡A«K»Ý³z¹L¤j¤À¤lÀç¾iª«(¤ñ¦p¸²µå¿}¡B¯×ªÕµ¥)ªº¤À¸Ñ¥HÀò±o¯à¶qªº¨Ñµ¹¡C

¹Ï¤@ ATP»PPCr¨Ï¥ÎÁC»ÄÁä¯à¶qªº±¡§Î
¡@¡@ºî¦X¤Wz¥iª¾¡APCr¦bÅ餺ªºÀx¦s¶q¬O¦³¤@©w¶qªº¡A¦]¦¹¡AÕY¯à°÷ºÉ¥i¯à¦a¼W¥[°©Àf¦Ù¤ºªºPCrÀx¦s¶q®É¡A±N¥i¯à¦³¤U¦C¥\¯à(McArdleµ¥¤H)¡G(1)¦bµu®É¶¡°ª±j«×¹B°Ê¤¤¡A«P¶iATPªº§Ö³tÂà´«¥Hºû«ù¨Åé§@¥\¯à¤O¡F(2)©µ¿ðPCrªº¯ÓºÉ¡F(3)°§CÁ޸ѧ@¥Îªº¥õ¿à©Ê¡A¶i¦Ó´î¤Ö¨Å»Ä(lactate)ªº¥Í¦¨¡F(4)¦b¤ÏÂЩʵu®É¶¡°ª±j«×¹B°Ê¤¤¡A³z¹LATP»PPCr¨³³t¦a¦A¦X¦¨¡A¦Ó«P¶i¦Ù¦×ªº©ñÃP»P«ì´_¡F§Ö³tªº«ì´_±N¦³§U©ó³sÄòªº°ª±j«×°V½m¡C
°Ñ¡B¦Ù»Ä»P¹B°Êªí²{
¡@¡@Harris(1992)¥H17¦W¨ü¸ÕªÌ¡A±ÄÀH¾÷¤À¬£Âùª¼¹êÅç³]p¡A¬ã¨s¤£¦PªºªA¥Î¦¸¼Æ(4*5g/d vs. 6*5g/d)»P¹B°Ê°V½m(1h/d³æ¸}½ñ¨®¹B°Ê)¡A¹ï¦Ù»Ä¸É¥R(CrH2O, creatine monohydrate)®ÄªGªº¼vÅT¡C¬ã¨sµ²ªGÅã¥Ü¡A¨C¤Ñ4©Î6¦¸ªº¦Ù»Ä¸É¥R¡A¬Ò¥iÅãµÛ´£ª@¦Ù»Ä§t¶q¡F¨C¤Ñ6¦¸²Õ¡A¨äÀx¦s¶q¼W¥[²v¸û§Ö(+32%)¡F¹B°Ê°V½m²Õ¨ä¦Ù»ÄÁ`Àx¶q¸ûµL¹B°Ê²Õ¬°°ª¡C
¡@¡@Balsom(1993a)¥H16¦W¨k©Ê¡AÀH¾÷¤À¬£¬°¦w¼¢¾¯²Õ»P¦Ù»Ä²Õ¡A±ÄÂùª¼¹êÅç³]p¡A³sÄò6¤é¤À§OªA¥Î6§Jªº½¦Ån¡A¶i¦æ¤Q¦¸¦U6ªWªº°ª±j«×¸}½ñ¨®¹B°Ê(140 rev/min)¥H¾ÉP°IºÜ¡A¬ã¨s¦Ù»Ä¸É¥R¹ï°ÊºA°ª±j«×¶¡·²¹B°Êªº¼vÅT¡C¬ã¨sµ²ªGÅã¥Ü¡A¦Ù»Ä²Õ¨ä¦Ù¦×¦Ù»Ä§t¶qÅãµÛ¼W¥[¡A¦Ó¦³®Ä©µ¿ð¤ÏÂЩʰª±j«×¹B°Ê®É¯h³Òªºµo¥Í¡F¬ã¨sªÌ»{¬°³o¥i¯à¬O¦]¬°¹B°Êªì´Á¸û°ªªºPCr¿@«×¡A»P¼W¥[«ì´_´ÁPCr¦A¦X¦¨ªº³t²v©ÒP¡A¦Ó¸û§Cªº¨Å»Ä»P¨È¶ÀÆP(hypoxanthine)ªº°ï¿n¤]¥i¯à¬Oì¦]¤§¤@¡C
¡@¡@Greenhaff (1993)¥H12¦W¨ü¸ÕªÌ¡A±ÄÂùª¼¹êÅç³]p¡AÀH¾÷¤À¬£¬°¦Ù»Ä²Õ(5 g Cr + l g¸²µå¿})»P¦w¼¢¾¯²Õ(6 g¸²µå¿})¡A¨C¤Ñ4¦¸³sÄòªA¥Î5¤Ñ¡AÀH«á¶i¦æ5¦^¦X¡A¨C¦^¦X30¦¸ªº³Ì¤j¦Û¥Dµ¥³t¦¬ÁY(180 0/s)´ú¸Õ¡A¬ã¨s¤fªA¦Ù»Ä¡A¹ï¤ÏÂЩʳ̤j¦Û¥D¦¬ÁY¦Ù¤Oªº¼vÅT¡C¬ã¨sµ²ªGÅã¥Ü¡A¦Ù»Ä²Õ¨ä¦Ù¦×¦Ù»Ä§t¶q¸û°ª¡A¥B©ó´ú¸Õ¹Lµ{¤¤¡A³Ì¤j¦Ù¤OÅãµÛ´£°ª¡B¦Ù¤O»¼´î²v¸û¤p¡C¥Ñ©ó¦Ù»Ä²Õ¦b¹B°Ê®Éªº¦å²M¤¤°ï¿n¸û¤Öªº®ò(ammonia)¡A¬ã¨sªÌ»{¬°¥i¯à¬O¥Ñ©óPCr¼W¥[¡A¨ÏATP¦A¦X¦¨§ó¦³®Ä²v¡A¦Ó©µ¿ð©Î´î½w¯h³Òªºµo¥Í¡C
¡@¡@Harris (1993)¥H10¦W¨k©Ê¤j¾Ç¤¤¶ZÂ÷¶]¹B°Êû¡AÀH¾÷¤À¬£¬°¦Ù»Ä²Õ»P±±¨î²Õ¡A³sÄò6¤é¨C¤ÑÄá¨ú6¦¸¦U10 g¡A¦¨¤À¤À§O¬°5 g CrH2O + 5 g¸²µå¿}(¦Ù»Ä²Õ)»P10g¸²µå¿}(±±¨î²Õ)¡A¬ã¨s6¤é¤fªA¦Ù»Ä¸É¥R¹ï³Ì¤j¶]¨B¹B°Êªº¼vÅT¡C¨ü¸ÕªÌ¥H¨ä³Ì¨Î¹B°Ê¦¨ÁZ90~95%ªº¶]³t¡A©ó¤£¦P¤Ñ¦U¶i¦æ4¦¸300¤½¤Ø¶]»P4¦¸1000¤½¤Ø¶]´ú¸Õ¡F¨C¦¸300¤½¤Ø¶]¬Ò¶¡¹j4¤ÀÄÁªº¥ð®§´Á¡A¨C¦¸1000¤½¤Ø¶]¬Ò¶¡¹j3¤ÀÄÁªº¥ð®§´Á¡C¬ã¨sµ²ªGÅã¥Ü¡A¦Ù»Ä²Õ©ó6¤é¼W¸É¤§«á¡A³Ì«á¤@¦¸300¤½¤Ø¶]¨B®É¶¡ªº´î¤Öµ{«×©úÅã°ª©ó¦w¼¢¾¯²Õ(-0.7s vs. -0.3s)¡F³Ì¨Î1000¤½¤Ø¶]¦¨ÁZ¡A¦Ù»Ä²Õ¤]ÅãµÛ¸û¦w¼¢¾¯²Õ¬°§Ö(-5.5s vs. -1.6s)¡C
¡@¡@Balsomµ¥¤H(1993b)¡A¥H¨C¤Ñ20§J¡A«ùÄò6¤Ñªº¦Ù»Ä¼W¸É«á¡A©ó¸}½ñ¨®´ú¥\¾¹¤W¹ê¬I(1)5¦¸6¬íÄÁ¤ÏÂнĨë´úÅç¡A¨C¦¸´úÅç¶¡¥ð®§30¬í¡F(2)10¬íÄÁ½Ä¨ë´úÅç¡F¦b´úÅ礧«á¡A¥ß§Y¥H¬¡Åé¦Ù¦×¬ï¨ëªk(muscle biopsy)±Ä¼Ë¡Aµ²ªGµo²{¼W¸É«áÅ餺¦Ù»Ä¿@«×©úÅã¼W¥[(129~152 mM/kg dry wt)¡A¤ÏÂнĨë«á¦Ù¦×¤¤¨Å»Ä¿@«×¸û§C(26 vs. 44 mM/kg dry wt)¡A10¬í½Ä¨ë«á¤u§@¿é¥X¶q¼W¥[¡CCaseyµ¥¤H(1996)¡A©ó¨C¤é20§J¡A«ùÄò5¤Ñªº¦Ù»Ä¼W¸É«á¡A¹ê¬I2¦¸30¬íªº½ñ¨®´úÅç¡Aµo²{Á`¤u§@¶q´£°ª4%¡A¥B´î¤ÖATPªº¤U°¹F31%¡CEarnestµ¥¤H(1995)¡A¥H¨C¤éªA¥Î20§J¡A«ùÄò28¤Ñªº¦Ù»Ä«á¶i¦æ(1)3¦¸30¬íªºWingate´úÅç¡A¤¤¶¡¥ð®§5¤ÀÄÁ¡F(2)¥õª×±ÀÁ|1RM´ú¸Õ¡F(3)¥õª×±ÀÁ|70%1RMªº¤ÏÂЦ¸¼Æ´úÅç¡Fµ²ªGÅã¥Üµo²{¤T¶µ´úÅçªí²{¬Ò¦]¦Ù»Äªº¼W¸É¦ÓÅãµÛ´£°ª¡C
¡@¡@Izquierdoµ¥¤H(2002)Åý¨ü¸ÕªÌ(Âùª¼³]p¡A¦Ù»Ä²Õ9¤H¡A¦w¼¢¾¯²Õ10¤H)¦b¼W¸É¦Ù»Ä(20 g/¤Ñ¡Ñ5¤Ñ)¤§«á¡AÀËÅç¦Ù»Ä¼W¸É¹ï¦Ù¦×Ãzµo¤O¡B¦Ù@¤O»P½Ä¨ëªí²{ªº¼vÅT¡F¬ã¨sµ²ªGµo²{¦Ù»Äªº¼W¸É¡AÅãµÛ¦a¼W¥[¤F¨ü¸ÕªÌªºÅé«(79.4¨ì80.0¤½¤ç)¡B¥õª×±ÀÁ|¦Ü¯h³Òªº¦¸¼Æ(+21%)»P¥§¡¿é¥X¥\²v(+17%)¡BÃÛÁ|¦Ü¯h³Òªº¦¸¼Æ(+33%)»P¥§¡¿é¥X¥\²v(+20%)¡BÃÛÁ|1RMªº¦Ù¤O(+11%)¥H¤Î5¤½¤Ø½Ä¨ë¶]ªº¥§¡®É¶¡(-3%)¡F¦ý¦Ù»Äªº¼W¸É¹ï©ó¥õª×±ÀÁ|1RMªº¦Ù¤O¨ÃµLÅãµÛ«P¶i¡A¥B¹ï©ó6¦¸«½Æ15¤½¤Ø½Ä¨ëªº@¤Oªí²{¥çµL¼W¶i®ÄªG¡C
¡@¡@McArdleµ¥¤H(2001)ªº®Ñ¤¤§ó¶i¤@¨B¦a¾ã²z¤F¸É¥R¦Ù»Ä¤§«á¡A¹ï©óÅ餺»P¹B°Êªí²{ªº¼vÅT¾÷¨î¡C¦Ù»Äªº¼W¸É¦³§U©ó¦Ù¦×¤º¦Ù»Ä»PPCrÀx¦s¶qªº´£¤É¡A¦]¦Ó¤@¤è±´£°ª¤F¹B°Ê«eÅ餺PCrªº§t¶q¡A¥t¤@¤è±«h¥Ñ©ó¦ÙÅÖºû¤º¦Ù»Ä§t¶qªº¼W¥[¡A´£°ª¤F²ÓMªºº¯³z©Ê¦ÓÅý²ÓM®e¶qÂX¤j¡C¹B°Ê«eÅ餺PCr§t¶qªº´£°ª¡A±N¦³§U©ó°§C¨Åé¹ï©óÁ޸ѧ@¥Î¥\¯àªº¨Ì¿à¡A´î¤Ö¨Å»Äªº¥Í¦¨¡A©µ½wpHȪº¤U°¡A¶i¦Ó©µ¿ð¯h³Òªºµo¥Í¡F¦AªÌ¡A¦Ù¦×¤º¦Ù»Ä»PPCr§t¶qªº¼W¥[¡A¦³§U©óPCr¦A¦X¦¨³t²vªº´£¤É¡A¦]¦¹¡A¹ï©ó¤ÏÂЩʰª±j«×µu®É¶¡¹B°Ê°V½m±N¦³©Ò§U¯q¡F°£¦¹¤§¥~¡A²ÓM®e¶qªºÂX¤j¡A¬O¥Ñ©ó²ÓM¤ô¦Xª¬ºA(hydration status)ªº¼W¥[¡A³J¥Õ½è¦X¦¨¤]¦]¦¹¦ÓÀH¤§¼W¥[¡A¶i¦Ó¨Ï±o¥h¯×Åé«(fat-free mass)¼W¥[¡A´£°ª°V½mªº±j«×¥H¤Îµu®É¶¡ªº¹B°Êªí²{¡C
¡@¡@ÁöµM¦p¦¹¡A¤]¦³¤@¨Ç¬ã¨s³ø§i¨Ã¤£¤ä«ù¤fªA¦Ù»Ä¦³§U©ó¹B°Êªí²{ªº½×ÂI(¨£ªí¤@)¡C¦]¦¹¡A¹ï©ó¤fªA¦Ù»Äªº©ú½T®ÄªG¡A¤´¦³«Ý¶i¤@¨B¤j¼Ë¥»ªº¹êÅç¬ã¨s¡A¥HÂç²M¤fªA¦Ù»Äªº¼vÅT¼h±¡C°£¦¹¤§¥~¡AGreenhaffµ¥¤H(1994)¥H8¦W¨ü¸ÕªÌ¸g20g/day¡Ñ5¤Ñªº¦Ù»Ä¼W¸É«á¡Aµo²{¨ä¤¤¦³5¦ì¨ü¸ÕªÌªºÅ餺¦Ù»Ä¿@«×©úÅã´£¤É(¡Ï19~35 mM/kg d.m.)¡A¦ý¬O¨ä¥¦3¦ì¨ü¸ÕªÌ«o¥u¼W¥[8~9 mM/kg d.m.¡F¦]¦¹¡AGreenhaffµ¥¤H´£¥X¦Ù»ÄªºªA¥Î¥i¯à¦³¡u¤ÏÀ³ªÌ»P¤£¤ÏÀ³ªÌ¡v¤§®t²§¡CGreenhaff±N°Ñ»P¦¹¬ã¨sªº©Ò¦³¨ü¸ÕªÌ¡A§@Å餺즳¦Ù»Ä¿@«×ªº¤ÀªRµo²{¡A¤ÏÀ³ªÌªº¥§¡¦Ù»Ä¿@«×§C©ó120 mM/kg d.m.¡A¤£¤ÏÀ³ªÌªº¥§¡¦Ù»Ä¿@«×°ª©ó130 mM/kg d.m.¡C³o¦ü¥GÅã¥Ü¡A·íì¥ýÅ餺¦Ù»Ä¿@«×¸û§C®É(¨Ò¦p¯À¹ªÌ)¡A¦Ù»Äªº¼W¸É¥i¯à·|¦³¸ûÅãµÛªº®ÄªG¡C¦]¦¹¡A¥¼¨Ó°w¹ï¦Ù»Ä¼W¸Éªº¬ã¨s¡A¦ü¥G¦³¥²n±N¤ÏÀ³ªÌ»P¤£¤ÏÀ³ªÌ¥[¥H¤ÀÃþ¡A¥HÂç²M¦Ù»Ä¼W¸Éªº½T¹êªG®Ä¡C
ªí¤@ ¤fªA¦Ù»Ä¹ï¹B°Êªí²{ªº¼vÅT
| §@ªÌ | ªA¥Î¾¯¶q | ¨ü¸ÕªÌ | ¹B°Ê´ú¸Õ¤º®e | µ²ªG |
| Mujika(1996) | 20g ¡Ñ 5¤Ñ | 20¤H | 25, 50, 100m´åªa | ¦¨ÁZªí²{¨S¦³¶i¨B |
| Terrillion(1997) | 20g ¡Ñ 5¤Ñ | 12¤H | 2¡Ñ700m¶]¨B(¶¡¹j¥ð®§2¤ÀÄÁ) | ¦¨ÁZªí²{¨S¦³¶i¨B |
| Burke(1996) | 20g ¡Ñ 5¤Ñ | 32¤H | 25, 50, 100m´åªa | ¦¨ÁZªí²{¨S¦³¶i¨B |
| Thompson(1996) | 2g/¤Ñ¡Ñ 6¶g | 10¤H | 100, 400m´åªa | ¦¨ÁZªí²{¨S¦³¶i¨B |
¡°¸`¿ý¦ÛDemant., T.W., & Rhodes., E.C. (1999). Effects of creatine supplementation on exercise performance. Sports Medicine, 28 (1), 49-60.
¸v¡B¦Ù»Ä¼W¸Éªk
¡@¡@¦Ù»Äªº¼W¸É¡A¤@¯ë¨Ã¤£·|¥HÁC»Ä¦Ù»Äªº«¬¦¡³c°â¡A¦Ó¬O¥H¥[¤WÁC»ÄÆQ¦¨¬°§t¤@¤À¤l¤ôªº¦Ù»Ä(CrH2O, creatine monohydrate)«¬¦¡³c°â¡C¥«±¤W©Ò³c°âªº¦Ù»Ä«¬¦¡¡A¥ç¦³¯»¥½¡B¿õ¾¯¡B½¦Ån»P²GºAª¬µ¥µ¥¤§¤À¡C¤@¯ë¨Ï¥Î¦Ù»Ä¼W¸Éªk(creatine loading)ªºì«h¬°¨C¤Ñ20~30 g¡A¨Ã³sÄòªA¥Î5~7¤Ñ(McArdleµ¥¤H)¡C

¹Ï¤G A. ·í³sÄò¸É¥R¦Ù»Ä6¤Ñ«á¡A°±¤î¦Ù»Ä¤§¸É¥R®É¡AÅ餺¦Ù»Ä¿@«×¤§ÅܤƱ¡§Î¡FB. ·í³sÄò¸É¥R¦Ù»Ä6¤Ñ¤§«á¡A±Ä¥Î§C¾¯¶q¦Ù»Ä¤§¸É¥R¤è¦¡®É¡AÅ餺¦Ù»Ä¿@«×¤§ÅܤƱ¡§Î
¡@¡@Hultmanµ¥¤H(1996)ªº¬ã¨sÅã¥Ü¤F¦Ù»Ä¼W¸Éªººû«ù®ÄªG¡C¬ã¨sªÌ±N¨ü¸ÕªÌ¤À¦¨¨â²Õ¡A¤@²Õ¬°¨C¤ÑÄá¨ú20g(¬ù¬°¨C¤½¤çÅé«Äá¨ú0.3 g)¡A¦@³sÄò6¤Ñ¡AµM«á°±¤î¸É¥R¡F¥t¤@²Õ°£¤F»P«e¤@²Õ¬Û¦P³sÄòÄá¨ú¦Ù»Ä6¤Ñ¤§¥~¡A¦b²Ä7¤Ñ«h¶}©l¨C¤ÑÄá¨ú2g(¬ù¬°¨C¤½¤çÅé«Äá¨ú0.03 g)³sÄò28¤Ñ¡C¬ã¨sªÌ¦b¹êÅç¶}©l«áªº²Ä7¡B21»P35¤Ñ¶i¦æ¦Ù¦×¬ï¨ëªk¥H¤ÀªR¦Ù¦×¤º¦Ù»Äªº¿@«×¡C¦¹¬ã¨sµ²ªGµo²{¡A¦b³sÄò6¤ÑÄá¨ú¦Ù»Ä¤§«á¡A¦Ù¦×¤º¦Ù»Ä¿@«×¼W¥[¤j¬ù20%¡F·í°±¤î¸É¥R¦Ù»Ä®É¡AÅ餺¦Ù»Ä§t¶q«K¶}©l¤U·Æ¡AµM¦Ó¦b«ùÄò§C¾¯¶q¸É¥R®É¡AÅ餺¦Ù»Ä¿@«×±N¥iºû«ù¦Ü¤Ö28¤Ñ¥H¤W(¨£¹Ï¤G)¡C¦]¦¹¡AMcArdleµ¥¤H«h»{¬°¦Ù»Ä¼W¸Éªº§Ö³t¤èªk¬O¡A³sÄò¼W¸É6¤Ñ¡A¨C¤Ñ4¦¸¡A¨C¦¸5§J(¦@20§J)ªºCrH2O¡A«K¨¬¥HÅýÅ餺¦Ù»Ä§t¶q¹F¹¡©Mª¬ºA¡FÀH«á¡AÕY±NªA¥Î¾¯¶q°§C¦Ü¨C¤Ñ2§J¡A«K¯à«ùÄòºû«ù°ª¿@«×ªº¦Ù»Ä¿@«×¡C¦ÓWilliams(1998)ªº®Ñ¤¤«h´£¨ì¡A¥t¤@ӦٻļW¸Éªkªº½wºC¤è¦¡¡A¥ç§Y¨C¤ÑÄá¨ú3§J¡A«ùÄò1Ӥ뤧«á¡A«K¯àÅýÅ餺¦Ù»Ä§t¶q¹F¨ì¹¡©M¡C
¥î¡B¼vÅT¦Ù»Ä¼W¸Éªº¦]¯À
¡@¡@¼vÅT¦Ù»Ä¼W¸Éªº¦]¯À°£¤F²Ä°Ñ¸`©Òzªº¤ÏÀ³ªÌ»P¤£¤ÏÀ³ªÌ(Greenhaffµ¥¤H)¤§¥~¡AÁÞÃþªºÄá¨ú»P©@°Ø¦]ªº¨Ï¥Î§¡·|¼vÅT¦Ù»Äªº¼W¸É®ÄªG¡CGreenµ¥¤H(1996)±N¨ü¸ÕªÌ¤À¦¨¨â²Õ¡A¤@²Õ¬°¦Ù»Ä²Õ(¨C¦¸5g¡A¨C¤Ñ4¦¸¡A³sÄò5¤Ñ)¡A¥t¤@²Õ¬°¦Ù»Ä¡ÏÁÞÃþ²Õ¡A¥ç§Y°£¤F¨C¦¸5 gªº¦Ù»Ä¡A¨C¤Ñ4¦¸¡A³sÄò5¤Ñ¤§¥~¡A¦b¨C¦¸Äá¨ú¦Ù»Ä«áªº30¤ÀÄÁ¡A¥t¥~Äá¨ú93gªº°ªGIÁÞÃþ(¨C¤Ñ4¦¸)¡C¬ã¨sµ²ªGµo²{¡A¦Ù»Ä²Õ¦bªA¥Î¦Ù»Ä¤§«á¡AÅãµÛ¦a¼W¥[¦Ù¦×PCr§t¶q(+7.2%)¡B´åÂ÷¦Ù»Ä(+13.5%)»PÁ`¦Ù»Ä¶q(+20.7%)¡F¦Ó¦Ù»Ä¡ÏÁÞÃþ²Õ«hÅãµÛ¦a¼W¥[¦Ù¦×PCr§t¶q(+14.7%)¡B´åÂ÷¦Ù»Ä(+18.1%)»PÁ`¦Ù»Ä¶q(+33.0%)¡C¦]¦¹¡A¬ã¨sªÌ»{¬°ÁÞÃþªº¨Ï¥Î¡A±N¦³§U©ó¦Ù»ÄªºÀx¦s¡A¦ÓMcArdleµ¥¤H«h»{¬°³oºØ²{¶H»P¯Ø®q¯Àªº¤Àªc¦³Ãö¡A¥ç§YÁÞÃþªºÄá¨ú¡A¨ë¿E¤FÅ餺¯Ø®q¯Àªº¤Àªc¡A¦]¦Ó¨Ï±o¦Ù¦×¤º¥iÀò±o¸û¦hªºÁÞÃþ»P¦Ù»Ä¡C
¡@¡@Nelsonµ¥¤H(2001)Åý12¦ì¨ü¸ÕªÌ¦b¹B°Ê¦Ü°IºÜ«á¡A¹ê¬I¨xÁÞ¶W¸Éªk(ÄṤñ²v¡ACHO: fat: protein¡A80: 10: 10)3¤Ñ¤§«á¡A¥ß§Y¼W¸É5¤Ñªº¦Ù»Ä(¤@¤Ñ4¦¸¡A¨C¦¸5g)¡AµM«á¦A¶i¦æ¹B°Ê¦Ü°IºÜ«áªº¨xÁÞ¶W¸Éªk3¤Ñ¡A¨Ã§Q¥Î¦Ù¦×¬ï¨ëªk¤ÀªR¦Ù¦×¤ºªº¨xÁÞ»P¦Ù»Ä¤§§t¶q(¬ï¨ë®É¶¡¬°²Ä1¡B4¡B11»P14¤Ñ)¡A¥H¬ã¨s¨xÁÞ¶W¸Éªk¬O§_·|¨ü¨ì¦Ù»Ä¼W¸É¼vÅT¡C¬ã¨sµ²ªGÅã¥Ü¦b²Ä¤@¦¸¨xÁÞ¶W¸Éªk«á¡A¦Ù¨xÁÞ§t¶q¼W¥[4%(164 mM/kg d.m.)¡A¦Ó¦Ù»Ä§t¶qµLÅܤơF¦b¦Ù»Ä¼W¸É¤§«á¡A¥ª¸}¦Ù»Ä§t¶q¤W¤É41.1 mM/kg d.m.¡A¥k¸}«h¤W¤É36.6 mM/kg d.m.¡A¦Ó¦Ù¨xÁÞ§t¶q«hµLÅܤơFµM¦Ó¡A¦b²Ä¤G¦¸¹ê¬I¨xÁÞ¶W¸Éªk¤§«á¡A¦Ù¨xÁÞ§t¶q«h¼W¥[¤F53%(241 mM/kg d.m.)¡C¸Ó¬ã¨sªÌ̦]¦Ó»{¬°¦Ù»Äªº¼W¸É¡A±N¥i¥HÂX¤jÀH«áªº¨xÁÞ¶W¸É®ÄªG¡A¥L̤]«ü¥X³oºØ²{¶H¥i¯à»P¦Ù»Ä¼W¸É¨ë¿E¤F²ÓM®e¶qªºÂX¤j¦³Ãö¡C¥Ñ¤Wz¤åÄm¥iª¾¡A¦Ù»Ä»PÁÞÃþªº°t¦X¨Ï¥Î¡A±N¯àÂX¤j©¼¦¹ªº¼W¸É®ÄªG¡C
¡@¡@¦b©@°Ø¦]¹ï¦Ù»Ä¼W¸É®ÄªGªº¼vÅT¤è±¡AVandenbergheµ¥¤H(1996)±N¨ü¸ÕªÌ¤À¦¨¤T²Õ¡A¤@²Õ¬°¦w¼¢¾¯²Õ¡A¤@²Õ¬°¦Ù»Ä²Õ(¨C¤ÑÄá¨ú0.5 g/kgÅé«¡A³sÄò6¤Ñ)¡A¥t¤@²Õ¬°¦Ù»Ä¡Ï©@°Ø¦]²Õ(¨C¤ÑÄá¨ú0.5 g/kgÅ髪º¦Ù»Ä¥H¤Î5 mg/kgÅ髪º©@°Ø¦]¡A³sÄò6¤Ñ)¡C¬ã¨sµ²ªGµo²{¡A¦Ù»Ä²Õ»P¦Ù»Ä¡Ï©@°Ø¦]²Õ¦Ù¦×¤ºªºPCr§t¶q¤À§O¼W¥[¤F4%»P6%¡A¦Ó¦w¼¢¾¯²Õ«hµLÅãµÛÅܤơC¦]¦¹¡A©@°Ø¦]ªº¦ñÀH¨Ï¥Î¡A¦ü¥G¹ï©ó¦Ù»Äªº¼W¸É¦³t±ªº¼vÅT¡A¸Ó¬ã¨sªÌ«h«ØÄ³¦b¹ê¬I¦Ù»Ä¼W¸Éªk®É¡A¹B°ÊûÀ³¸ÓÁ×§K©@°Ø¦]ªº¨Ï¥Î¡C
³°¡Bµ²»y
¡@¡@¦Ù»Ä¼W¸Éªº®ÄªG¡A¥Dn§@¥Î©óÅ餺ATP-PCr¨t²Î¡AÃB¥~ªº¦Ù»Ä¸É¥R¡A¦³§U©ó´£°ªÅ餺´åÂ÷¦Ù»Ä»PÁC»Ä¦Ù»ÄªºÀx¦s¶q¡A¼W¶iÅ餺µu®É¶¡°ª±j«×ªº¯à¶q¨Ó·½¡A¶i¦Ó´£¤Éµu®É¶¡ªº¹B°Êªí²{¡C¼vÅT¦Ù»Ä¼W¸Éªº¦]¯À¡A«h¥]¬AÅ餺ì¥ýªº¦Ù»Ä§t¶q(¥ç§Y©Ò¿×ªº¤ÏÀ³ªÌ»P¤£¤ÏÀ³ªÌ)¡B¬O§_¦ñÀHÁÞÃþªº¸É¥R¥H¤Î©@°Ø¦]ªº¨Ï¥Î»P§_µ¥¡A³o¨Ç¦]¯À±N¼vÅTµÛ¦P¶q¦Ù»Ä¼W¸É«á¡AÅ餺«O¦s¶qªº¦h¹è¡C
¡@¡@ÁöµM¦Ù»Ä¼W¸Éªº®ÄªG¦ü¥G¬Û·íÅãµÛ¡A¨º»ò¡A¦Ù»ÄªºÃB¥~¼W¸É¬O§_·|³y¦¨¤HÅ骺°Æ§@¥Î©O¡HºI¦Ü¥Ø«e¬°¤î¡A¬ã¨s³ø§i¨Ã¤£¨¬¥H´£¨Ñ©ú½Tªºµª®×¡A¤ñ¦pWillamsªº®Ñ¤¤´£¨ì¡A¦Ù»Äªº¼W¸É¥i¯à·|¦]¬°Å餺§t¤ô¶qªº¼W¥[¼vÅT¹q¸Ñ½èªº¥¿Å¡A¦Ó¾ÉP¦Ù¦×ªºµjÅË¡F¦ÓMcArdleµ¥¤H«h»{¬°ªø®É¶¡(4¦~)¦Ù»Äªº¼W¸É¡A¹ï¤HÅé¨ÃµL¤jê¡CµM¦Ó¡A¸û©ú½Tªº¬O¡A¦Ù»ÄªºÃB¥~¸É¥R¡A·|¼W¥[²ÓMªºº¯³z©Ê¡A¦]¦Ó¨Ï±o²ÓM®e¶q¼W¥[¡A¾ÉPÅ髪º¤W¤É¡A¦ÓÅ髪º¤W¤É¡A¹ï¬Y¨Ç¹B°Ê¶µ¥Ø¨Ó»¡¡A«K¥i¯à¬O¤@t±ªº¤zÂZ¡A¨Ò¦p@¤O©Ê¹B°Ê¶µ¥Ø¡AÅ髪º¼W¥[¨Ï±o¨Åé¦b°V½m©Î¤ñÁɮɡA¥²¶·©Ó¨ü¸û¤jªº¨Åét«¡A¦Ó¼W¥[®ñ®ø¯Ó¶q¡A¦]¦¹¡A¦bªA¥Î¦Ù»Ä®É¡A¥²¶·¦Ò¶q¹B°Ê¶µ¥Øªº¯S®í©Ê¥H¤Î¦Ù»Ä¼W¸É©Ò³y¦¨ªºÅ髼W¥[°ÝÃD¡C
°Ñ¦Ò¤åÄm
±iīī¡C¥Á88¡C¦Ù»Ä¼W¸É¹ï¹B°Êªí²{ªº¼vÅT¡C¤¤µØÅé¨|¡A12 (5)¡A62-68¶¡C
Balsom, P. D., Ekblom, B., Soderlund, B., Sjodin, B., & Hultman, E. (1993a). Creatine supplementation and dynamic high-intensity intermittent exercise. Scand J Med Sci Sports, 3, 143-149.
Balsom, P. D., Harridge, K., Soderlund, B., Sjodin, B., & Ekblom, B. (1993b). Creatine supplementation per se does not enhance endurance performance. Acta Physiological Scandinavia, 149 (4), 521-523.
Casey, A., Constantin-Teodosiu, D., Howell, D., Hultman, E., & Greenhaff, P. (1996). Creatine ingestion favorably affects performance and muscle metabolism during maximal exercise in humans. American Journal of Physiology, 271, E31-37.
Demant, T.W., & Rhodes, E.C. (1999). Effects of creatine supplementation on exercise performance. Sports Medicine, 28 (1), 49-60.
Earnest, C., Snell, P., Rodriguez, R., Almada, A., & Mitchell, T. (1995). The effect of creatine monohydrate ingestion on anaerobic power indices, muscle strength and body composition. Acta Physiologiacl Scandinavia, 153, 207-209.
Green, A. L., Hultman, E., Macdonald, I. A., Sewell, D. A., & Greenhaff, P. L. (1996). Carbohydrate ingestion augments skeletal muscle creatine accumulation during creatine supplementation in humans. American Journal of Physiology, 271, E821-826.
Greenhaff, P.L., Bodin, K., & Soderlund, K. (1994). Effects of oral creatine supplementation on skeletal muscle phosphocreatine resynthesis. American Journal of Physiology, 266, E725-730.
Greenhaff, P. L., Casey, A., Short, A. H., Harris, R., Soderlund, K., & Hultman, E. (1993). The influence of oral creatine supplementation on muscle torque during repeated bouts of maximal voluntary exercise in man. Clinical Science, 84, 565-571.
Harris, R. C., Soderlund, K., & Hultman, E. (1992). Elevation of creatine in resting and exercised muscle of normal subjects by creatine supplementation. Clinical Science, 83, 367-374.
Harris, R. C., Viru, M., Greenhaff, P. L., & Hultman, E. (1993). The effect of oral creatine supplementation on running performance during maximal short term exercise in man (abstract). Journal of Physiology, 467, 74P.
Hultman, E., Soderlund, K., Timmons, J. A., Cederblad, G., & Greenhaff, P. L. (1996). Muscle creatine loading in men. Journal of Applied Physiology, 81 (1), 232-237.
Izquierdo, M., Ibañez, J., González-Badillo, J. J., & Gorostiaga, E. M. (2002). Effects of creatine supplementation on muscle power, endurance, and sprint performance. Medicine and Science in Sports and Exercise, 34 (2), 332-343.
McArdle, W. D., Katch, F. I., & Katch, V. L. (2001). Exercise Physiology: Energy, Nutrition, and Human Performance (5th ed., pp.583-588). Baltimore: Lippincott Williams & Wilkins.
Nelson, A. G., Arnall, D. A., Kokkonen, J., Day, R., & Evans, J. (2001). Muscle glycogen supercompensation is enhanced by prior creatine supplementation. Medicine and Science in Sports and Exercise, 33 (7), 1096-1100.
Vandenberghe, K., Gillis, N., Van Leemputte, M., Van Hecke, P., Vanstapel, F., & Hespel, P. (1996). Caffeine counteracts the ergogenic action of creatine loading. Journal of Applied Physiology, 80 (2), 452-457.
Williams, M. H. (1998). The Ergogenics Edge: Pushing the Limits of Sports Performance (pp.178-182). Champaign, IL: Human Kinetics.